Business Description
CDT Equity Inc. is a clinical-stage pharmaceutical company focused on developing treatments for autoimmune conditions and male infertility where effective options are currently lacking. Its two lead drug candidates, AZD1656 and AZD5904, have each completed Phase I trials targeting conditions such as type 2 diabetes, organ transplant rejection, thyroid disease, and idiopathic male infertility. The company works with Agility Life Sciences to develop new oral medication formulations. Founded in 2019 and headquartered in Naples, Florida, CDT Equity was previously known as Conduit Pharmaceuticals Inc. before rebranding in August 2025.
